ストックスクリーナーアプリを入手
1.28
3.23%
0.04
アフターアワーズ：
1.25
-0.03
-2.34%
MAIA Biotechnology Inc (MAIA) 最新ニュース
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Cash Flow - TradingKey
MAIA Biotechnology Edges Lower as Support Level Faces TestVol Target Rebalance - Bölüm Sonu Canavarı
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA) - The Globe and Mail
Data released by MAIA Biotechnology Inc. show that the combination therapy of its candidate drug Apatganosin with Ximiprilizumab demonstrated an acceptable safety profile in a heavily pre-treated population of patients with advanced solid tumors. - Bitget
Maia Biotechnology Reports Initial Efficacy Data from Phase 2 Thio-101 Part C Expansion Trial in Third-Line Non-Small Cell Lung Cancer - marketscreener.com
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - The Manila Times
MAIA Biotechnology Reports 90.5% Interim Disease Control Rate in Phase 2 THIO-101 Part C for Advanced NSCLC - Quiver Quantitative
MAIA Biotechnology Reports Strong Initial Efficacy Data in - GlobeNewswire
MAIA Biotechnology (MAIA) Faces Selling Pressure as Shares Approach Key SupportIPO Entry Watch - dars.gov.et
MAIA Biotechnology Inc. (MAIA) Rises 3.1% as Shares Approach Key ResistanceVolume Profile - DonanımHaber
Enterprise value to EBITDA forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView
Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView
MAIAMAIA Biotechnology Inc Dividends - Finviz
ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView
MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan
MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike - Stock Titan
Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant - Stock Titan
26,355 stock options granted to MAIA (NASDAQ: MAIA) director Jean-Manasse - Stock Titan
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et
MAIA Forecast — Price Target — Prediction for 2027 - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView
Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media
MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan
Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal
MAIA Biotechnology completes international enro... - Pluang
MAIA Biotechnology (MAIA) Edges Higher Amid Biotech Sector Interest — Key Levels in FocusCTA Positioning - dars.gov.et
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
MAIA Should I Buy - Intellectia AI
MAIA Gains on Setting up New Site - Baystreet.ca
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion - GlobeNewswire
MAIA Biotechnology opens patient enrollment at ... - Pluang
MAIA Biotechnology Surges 4.6%, Approaches Key Resistance at $1.43MESA MA - newsline.com
MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com
MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower Loss and Pipeline Progress Signal Operational DisciplineDividend Increase Stocks - dars.gov.et
MAIA Biotechnology Activates Second US Site for Phase 2 Trial of Lung Cancer Treatment - Moomoo
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - The Manila Times
MAIA Biotechnology Activates and Opens Enrollment at Second - GlobeNewswire
MAIA Q1 2026 Earnings: EPS Beat on Lower Net Loss, Focus on Clinical PipelineConsensus Beat Rate - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Consistency Score - newsline.com
FDA Clears US Enrollment for Ateganosine Phase 2 NSCLC Trial Expansion - Targeted Oncology
MAIA Biotechnology Inc. (MAIA) announced that its pivotal Phase III clinical trial for non-small cell lung cancer is showing strong momentum in patient enrollment and dosing. - Bitget
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - The Manila Times
MAIA Biotechnology Reports Patient Enrollment Progress in Phase 3 Trial of Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer - Quiver Quantitative
Lung cancer trial drug saw 17.8-month survival vs 5.8 on chemo in MAIA study - Stock Titan
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):